Startups
Biotechnology / COVID-19 / Health

Gaithersburg’s Novavax moves into phase 3 of its of COVID-19 vaccine trial

This clinical trial, which will be conducted in the U.K., will focus on evaluating the candidate's safety, efficacy and ability to provoke an immune response.

Novavax is running trials for its COVID-19 vaccine candidate. (Courtesy photo)

After beginning clinical trials in May, Gaithersburg, Maryland-based Novavax has moved its COVID-19 vaccine candidate into phase three of testing.

The clinical-stage biotech company that develops vaccines to prevent serious infectious diseases gained hundreds of millions of dollars to advance its vaccine candidate this year. Back in May, Novavax conducted phase one and two clinical trials of its coronavirus vaccine on 130 healthy participants ages 18 to 59 in Australia, and shared the positive results of those trials in August.

This phase-three clinical trial will focus on evaluating the candidate’s safety, efficacy and ability to provoke an immune response. The trial is being conducted over the next four to six weeks in the United Kingdom in partnership with the British government’s Vaccines Taskforce.

“The data from this trial is expected to support regulatory submissions for licensure in the UK, EU and other countries,” said Novavax’s president of research and development, Gregory M. Glenn, M.D., in a statement. “We are grateful for the support of the UK Government, including from its Department of Health and Social Care and National Institute for Health Research, to advance this important research.”

Novavax is conducting the phase three trial of its coronavirus vaccine on on up to 10,000 participants ages 18 to 84. Half of the trial participants will receive two muscle injections administered 21 days apart while the other participants will receive placebos. At least 25% of the trial will target participants over the age of 65 and other specific groups most affected by the coronavirus, like racial minorities. Up to 400 participants total will also receive a flu shot as part of a sub-study.

For transparency, Novavax plans to share its U.K. study protocol publicly soon. A preliminary analysis of the trial’s results will be conducted when at least 67% of participants who show any coronavirus symptoms have received the vaccine.

The company is one of 11 worldwide to reach this third phase of testing, per The New York Times.

Series: Coronavirus

Before you go...

Please consider supporting Technical.ly to keep our independent journalism strong. Unlike most business-focused media outlets, we don’t have a paywall. Instead, we count on your personal and organizational support.

3 ways to support our work:
  • Contribute to the Journalism Fund. Charitable giving ensures our information remains free and accessible for residents to discover workforce programs and entrepreneurship pathways. This includes philanthropic grants and individual tax-deductible donations from readers like you.
  • Use our Preferred Partners. Our directory of vetted providers offers high-quality recommendations for services our readers need, and each referral supports our journalism.
  • Use our services. If you need entrepreneurs and tech leaders to buy your services, are seeking technologists to hire or want more professionals to know about your ecosystem, Technical.ly has the biggest and most engaged audience in the mid-Atlantic. We help companies tell their stories and answer big questions to meet and serve our community.
Contribute to the journalism fund Preferred partners Our services
Engagement

Join the conversation!

Find news, events, jobs and people who share your interests on Technical.ly's open community Slack

Trending

DMV coworking guide: 20 places to work, with company

5 local orgs with services and resources for startups and entrepreneurs

How 3 local orgs help founders and entrepreneurs build their networks

Axios and Quorum’s new tool could soon make following legislative developments easier

Technically Media